Tag: drug

PRESS RELEASE

Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is emerging as a leading legal alternative tailored for lean muscle tone, stamina, and strength—without synthetic risk.

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

PhenQ 2025 OTC Fat Burner for Men: Medically accredited supplement gains national traction with expert-backed multi-action formula and user trust.

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS), Sarepta (SRPT), or PetCo (WOOF) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), PepGen (PEPG), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon (OGN), UroGen (URGN), Red Cat (RCAT), or Fortrea (FTRE) To Contact Him Directly To Discuss Their Options

NEW YORK, July 12, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline.

Area 52 launches its new line of Disposable Weed Pens – backed by a 90-day 100% money back satisfaction guarantee.

IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline

Kuick Research Report highlights ongoing Clinical Development Technology platforms In Recent Research Study On KIF18A Therapies

CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).